1
|
Mi T, Zhang Z, Zhanghuang C, Jin L, Tan X, Liu J, Wu X, Li M, Wang J, Wang Z, Guo P, He D. Doxycycline hydrochloride inhibits the progress of malignant rhabdoid tumor of kidney by targeting MMP17 and MMP1 through PI3K-Akt signaling pathway. Eur J Pharmacol 2024; 964:176291. [PMID: 38158115 DOI: 10.1016/j.ejphar.2023.176291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Revised: 12/09/2023] [Accepted: 12/18/2023] [Indexed: 01/03/2024]
Abstract
OBJECTIVE To identify therapeutic targets for malignant rhabdoid tumors of kidney (MRTK) and to investigate the effects and underlying mechanism of doxycycline hydrochloride on these tumors. METHODS Gene expression and clinical data of MRTK were retrieved from the TARGET database. Differentially expressed genes (DEGs) and prognostic-related genes (PRGs) were selected through a combination of statistical analyses. The functional roles of MMP17 and MMP1 were elucidated through RNA overexpression and intervention experiments. Furthermore, in vitro and in vivo studies provided evidence for the inhibitory effect of doxycycline hydrochloride on MRTK. Additionally, transcriptome sequencing was employed to investigate the underlying molecular mechanisms. RESULTS 3507 DEGs and 690 PRGs in MRTK were identified. Among these, we focused on 41 highly expressed genes associated with poor prognosis and revealed their involvement in extracellular matrix regulatory pathways. Notably, MMP17 and MMP1 stood out as particularly influential genes. When these genes were knocked out, a significant inhibition of proliferation, invasion and migration was observed in G401 cells. Furthermore, our study explored the impact of the matrix metalloproteinase inhibitor, doxycycline hydrochloride, on the malignant progression of G401 both in vitro and in vivo. Combined with sequencing data, the results indicated that doxycycline hydrochloride effectively inhibited MRTK progression, due to its ability to suppress the expression of MMP17 and MMP1 through the PI3K-Akt signaling pathway. CONCLUSION Doxycycline hydrochloride inhibits the expression of MMP17 and MMP1 through the PI3K-Akt signaling pathway, thereby inhibiting the malignant progression of MRTK in vivo and in vitro.
Collapse
Affiliation(s)
- Tao Mi
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Zhaoxia Zhang
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Chenghao Zhanghuang
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Liming Jin
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Xiaojun Tan
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Jiayan Liu
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Xin Wu
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Mujie Li
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Jinkui Wang
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Zhang Wang
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China
| | - Peng Guo
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China
| | - Dawei He
- Children's Urogenital Development and Tissue Engineering Chongqing Key Laboratory, Chongqing, 400014, China; Chongqing Key Laboratory of Pediatrics, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China; Department of Urology, Children's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China; Key Laboratory of Children's Developmental Diseases Research, Affiliated Children's Hospital of Chongqing Medical University, Ministry of Education, Chongqing, 400014, China; National International Science and Technology Cooperation Base for Major Childhood Developmental Diseases, Children 's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China; National Clinical Research Center for Child Health and Diseases, Children 's Hospital Affiliated to Chongqing Medical University, Chongqing, 400014, China.
| |
Collapse
|
2
|
Hirahata T, ul Quraish R, Quraish AU, ul Quraish S, Naz M, Razzaq MA. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Inform 2022; 21:11769351221076062. [PMID: 35153470 PMCID: PMC8832574 DOI: 10.1177/11769351221076062] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 01/07/2022] [Indexed: 12/23/2022] Open
Abstract
Cancer is a leading cause of morbidity and mortality worldwide. Over the past decades, the concept of precision cancer medicine has emerged as a novel approach in the field of oncology that aims to tailor the most effective treatment options to each individual cancer patient based on the genetic profile of the tumor of each individual patient. Recently, tissue biopsy has become an essential part of cancer care and is widely used to characterize the tumor. However, tissue biopsy techniques face different challenges due to their invasiveness, cost, time, and adversity in potential sampling due to tissue heterogeneity. To overcome these issues, a non-invasive approach has developed, which is known as liquid biopsy. It is a simple, fast, and worthwhile technique based on the analysis of circulating tumor DNA (which is a fraction of cfDNA), circulating tumor cells (CTCs), and other tumor-derived material in blood plasma. This review provides an overview of the concept of liquid biopsy and briefly discusses the role of ctDNA and CTC analysis as tools for early diagnosis and prognosis of cancer. In this review, we also speculate on the advantages of liquid biopsy as opposed to tissue biopsy and postulate that liquid biopsy may be a comprehensive approach to overcome the current limitations associated with costly, invasive, and time-consuming tissue biopsy.
Collapse
Affiliation(s)
| | | | | | | | - Munazzah Naz
- Hirahata Gene Therapy Laboratory, HIC Clinic, Tokyo, Japan
| | | |
Collapse
|
3
|
Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray MJ, Schönberger S, Czech T, Schouten-van Meeteren AYN, Kordes U, Kramm CM, van Vuurden DG, Hulleman E, Janssens GO, Solanki GA, van Veelen MLC, Thomale U, Schuhmann MU, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford SC, Pfister SM, Van Gool SW. Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncol 2018; 19:e419-e428. [PMID: 30102236 DOI: 10.1016/s1470-2045(18)30364-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 05/07/2018] [Accepted: 05/08/2018] [Indexed: 12/24/2022]
Abstract
Paediatric CNS tumours are the most common cause of childhood cancer-related morbidity and mortality, and improvements in their diagnosis and treatment are needed. New genetic and epigenetic information about paediatric CNS tumours is transforming the field dramatically. For most paediatric CNS tumour entities, subgroups with distinct biological characteristics have been identified, and these characteristics are increasingly used to facilitate accurate diagnoses and therapeutic recommendations. Future treatments will be further tailored to specific molecular subtypes of disease, specific tumour predisposition syndromes, and other biological criteria. Successful biomaterial collection is a key requirement for the application of contemporary methodologies for the validation of candidate prognostic factors, the discovery of new biomarkers, the establishment of appropriate preclinical research models for targeted agents, a quicker clinical implementation of precision medicine, and for other therapeutic uses (eg, for immunotherapies). However, deficits in organisational structures and interdisciplinary cooperation are impeding the collection of high-quality biomaterial from CNS tumours in most centres. Practical, legal, and ethical guidelines for consent, storage, material transfer, biobanking, data sharing, and funding should be established by research consortia and local institutions to allow optimal collection of primary and subsequent tumour tissue, body fluids, and normal tissue. Procedures for the collection and storage of biomaterials and related data should be implemented according to the individual and organisational structures of the local institutions.
Collapse
Affiliation(s)
- Stefan Rutkowski
- Department of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
| | | | - Daniel Williamson
- Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK
| | - Kornelius Kerl
- Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Münster, Germany
| | - Karsten Nysom
- Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark
| | - Barry Pizer
- Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - Ute Bartels
- Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Stephanie Puget
- Department of Paediatric Neurosurgery, Necker Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - François Doz
- SIREDO Centre (Care, Innovation And Research In Paediatric, Adolescents and Young Adults Oncology), Institut Curie and Paris Descartes University, Paris, France
| | - Antony Michalski
- Department of Haematology and Oncology, Great Ormond Street Hospital for Children, London, UK
| | - Katja von Hoff
- Department of Paediatric Haematology and Oncology, Berlin, Germany; Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Mathilde Chevignard
- Rehabilitation Department for Children with Acquired Neurological Injury, Saint Maurice Hospitals, Saint Maurice, France; Laboratory of Biomedical Imaging, National Centre for Scientific Research and National Institute of Health and Medical Research, Sorbonne University, Paris, France
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's National Health Service Foundation Trust, Liverpool, UK
| | - Matthew J Murray
- Department of Pathology, University of Cambridge, Cambridge, UK; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK
| | - Stefan Schönberger
- Department of Paediatric Haematology and Oncology, University Children's Hospital Bonn, University of Bonn, Bonn, Germany
| | - Thomas Czech
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | | | - Uwe Kordes
- Department of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Christof M Kramm
- Division of Paediatric Haematology and Oncology, University Medical Centre Goettingen, Goettingen, Germany
| | - Dannis G van Vuurden
- Pediatric Oncology/Hematology, Department of Pediatrics, Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands
| | - Esther Hulleman
- Pediatric Oncology/Hematology, Department of Pediatrics, Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands
| | - Geert O Janssens
- Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands; Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands
| | - Guirish A Solanki
- Department of Paediatric Neurosurgery, Birmingham Women's and Children's Hospital, Birmingham, UK
| | - Marie-Luise C van Veelen
- Paediatric Neurosurgery, Department of Neurosurgery, Erasmus University Medical Centre Rotterdam, Netherlands
| | | | - Martin U Schuhmann
- Division of Paediatric Neurosurgery, Department of Neurosurgery, Eberhard Karls University Hospital of Tübingen, Tübingen, Germany
| | - Chris Jones
- Division of Molecular Pathology and Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Felice Giangaspero
- Department of Radiological, Oncological, and Anatomopathological Sciences, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed-Mediterranean Neurological Institute, Pozzilli, Italy
| | - Dominique Figarella-Branger
- AP-HM, CNRS, Institut de Neurophysiopathologie, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Aix-Marseille University, Marseille, France
| | - Torsten Pietsch
- Institute of Neuropathology, Brain Tumour Reference Centre of the German Society of Neuropathology and Neuroanatomy, University of Bonn Medical Centre, Bonn, Germany; German Centre for Neurodegenerative Diseases, Bonn, Germany
| | - Steve C Clifford
- Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK
| | - Stefan M Pfister
- Hopp Children's Cancer Centre at National Centre for Tumour Diseases Heidelberg (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Paediatric Haematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | | |
Collapse
|
4
|
Tran TH, Shah AT, Loh ML. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. Clin Cancer Res 2017; 23:5329-5338. [PMID: 28600472 DOI: 10.1158/1078-0432.ccr-16-0115] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Revised: 04/15/2017] [Accepted: 06/06/2017] [Indexed: 11/16/2022]
Abstract
Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors. Clin Cancer Res; 23(18); 5329-38. ©2017 AACR.
Collapse
Affiliation(s)
- Thai Hoa Tran
- Department of Pediatrics, Centre Mère-Enfant, Centre Hospitalier de l'Université Laval, Québec, Canada.,Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Canada
| | - Avanthi Tayi Shah
- Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.,Helen Diller Family Cancer Research Center, University of California, San Francisco, San Francisco, California
| | - Mignon L Loh
- Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, San Francisco, California. .,Helen Diller Family Cancer Research Center, University of California, San Francisco, San Francisco, California
| |
Collapse
|
5
|
Ershova ES, Jestkova EM, Chestkov IV, Porokhovnik LN, Izevskaya VL, Kutsev SI, Veiko NN, Shmarina G, Dolgikh O, Kostyuk SV. Quantification of cell-free DNA in blood plasma and DNA damage degree in lymphocytes to evaluate dysregulation of apoptosis in schizophrenia patients. J Psychiatr Res 2017; 87:15-22. [PMID: 27987480 DOI: 10.1016/j.jpsychires.2016.12.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Revised: 11/18/2016] [Accepted: 12/01/2016] [Indexed: 11/30/2022]
Abstract
Oxidative DNA damage has been proposed as one of the causes of schizophrenia (SZ), and post mortem data indicate a dysregulation of apoptosis in SZ patients. To evaluate apoptosis in vivo we quantified the concentration of plasma cell-free DNA (cfDNA index, determined using fluorescence), the levels of 8-oxodG in cfDNA (immunoassay) and lymphocytes (FL1-8-oxodG index, flow cytometry) of male patients with acute psychotic disorders: paranoid SZ (total N = 58), schizophreniform (N = 11) and alcohol-induced (N = 14) psychotic disorder, and 30 healthy males. CfDNA in SZ (N = 58) does not change compared with controls. In SZ patients. Elevated levels of 8-oxodG were found in cfDNA (N = 58) and lymphocytes (n = 45). The main sources of cfDNA are dying cells with oxidized DNA. Thus, the cfDNA/FL1-8-oxodG ratio shows the level of apoptosis in damaged cells. Two subgroups were identified among the SZ patients (n = 45). For SZ-1 (31%) and SZ-2 (69%) median values of cfDNA/FL1-8-oxodG index are related as 1:6 (p < 0.0000001). For the patients with other psychotic disorders and healthy controls, cfDNA/FL1-8-oxodG values were within the range of the values in SZ-2. Thus, apoptosis is impaired in approximately one-third of SZ patients. This leads to an increase in the number of cells with damaged DNA in the patient's body tissues and may be a contributing cause of acute psychotic disorder.
Collapse
Affiliation(s)
- E S Ershova
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia; V. A. Negovsky Research Institute of General Reanimatology, Moscow, 107031, Russia
| | - E M Jestkova
- Psychiatric Hospital № 14 of Moscow City Health Department, Moscow, 115447, Russia
| | - I V Chestkov
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia
| | - L N Porokhovnik
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia.
| | - V L Izevskaya
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia
| | - S I Kutsev
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia
| | - N N Veiko
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia; V. A. Negovsky Research Institute of General Reanimatology, Moscow, 107031, Russia
| | - G Shmarina
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia
| | - O Dolgikh
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia
| | - S V Kostyuk
- Research Centre for Medical Genetics (RCMG), Moscow, 115478, Russia; V. A. Negovsky Research Institute of General Reanimatology, Moscow, 107031, Russia
| |
Collapse
|
6
|
Chakravadhanula M, Hampton CN, Chodavadia P, Ozols V, Zhou L, Catchpoole D, Xu J, Erdreich-Epstein A, Bhardwaj RD. Wnt pathway in atypical teratoid rhabdoid tumors. Neuro Oncol 2014; 17:526-35. [PMID: 25246426 DOI: 10.1093/neuonc/nou229] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Atypical teratoid rhabdoid tumor (ATRT) is an aggressive pediatric brain tumor with limited therapeutic options. The hypothesis for this study was that the Wnt pathway triggered by the Wnt5B ligand plays an important role in ATRT biology. To address this hypothesis, the role of WNT5B and other Wnt pathway genes was analyzed in ATRT tissues and ATRT primary cell lines. METHODS Transcriptome-sequencing analyses were performed using nanoString platforms, immunohistochemistry, Western blotting, quantitative reverse transcriptase PCR, immunoprecipitation, short interference RNA studies, cell viability studies, and drug dose response (DDR) assays. RESULTS Our transcriptome-sequencing results of Wnt pathway genes from ATRT tissues and cell lines indicated that the WNT5B gene is significantly upregulated in ATRT samples compared with nontumor brain samples. These results also indicated a differential expression of both canonical and noncanonical Wnt genes. Imunoprecipitation studies indicated that Wnt5B binds to Frizzled1 and Ryk receptors. Inhibition of WNT5B by short interference RNA decreased the expression of FRIZZLED1 and RYK. Cell viability studies a indicated significant decrease in cell viability by inhibiting Frizzled1 receptor. DDR assays showed promising results with some inhibitors. CONCLUSIONS These promising therapeutic options will be studied further before starting a translational clinical trial. The success of these options will improve care for these patients.
Collapse
Affiliation(s)
- Madhavi Chakravadhanula
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Chris N Hampton
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Parth Chodavadia
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Victor Ozols
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Li Zhou
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Daniel Catchpoole
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Jingying Xu
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Anat Erdreich-Epstein
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| | - Ratan D Bhardwaj
- Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, Arizona (M.C., C.N.H., V.O., R.D.B.); Children's Hospital at Westmead, Sydney, Australia (L.Z., D.C.); Duke University, Durham, North Carolina (P.C.); Children's Hospital Los Angeles, Los Angeles, California (A.E.-E.); Children's Hospital Los Angeles and the University of Southern California, Los Angeles, California (J.X., A.E.-E.)
| |
Collapse
|
7
|
Expression of the HOX genes and HOTAIR in atypical teratoid rhabdoid tumors and other pediatric brain tumors. Cancer Genet 2014; 207:425-8. [DOI: 10.1016/j.cancergen.2014.05.014] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/23/2014] [Accepted: 05/31/2014] [Indexed: 01/04/2023]
|
8
|
Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 2014; 207:365-72. [PMID: 24853101 DOI: 10.1016/j.cancergen.2014.04.004] [Citation(s) in RCA: 99] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Revised: 04/01/2014] [Accepted: 04/02/2014] [Indexed: 02/02/2023]
Abstract
SMARCB1 (INI1/SNF5/BAF47), a core subunit of the SWI/SNF (BAF) chromatin-remodeling complex, is inactivated in the large majority of rhabdoid tumors, and germline heterozygous SMARCB1 mutations form the basis for rhabdoid predisposition syndrome. Mouse models validated Smarcb1 as a bona fide tumor suppressor, as Smarcb1 inactivation in mice results in 100% of the animals rapidly developing cancer. SMARCB1 was the first subunit of the SWI/SNF complex found mutated in cancer. More recently, at least seven other genes encoding SWI/SNF subunits have been identified as recurrently mutated in cancer. Collectively, 20% of all human cancers contain a SWI/SNF mutation. Consequently, investigation of the mechanisms by which SMARCB1 mutation causes cancer has relevance not only for rhabdoid tumors, but also potentially for the wide variety of SWI/SNF mutant cancers. Here we discuss normal functions of SMARCB1 and the SWI/SNF complex as well as mechanistic and potentially therapeutic insights that have emerged.
Collapse
|